Loss of gastrokine-2 drives premalignant gastric inflammation and tumor progression

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

| Citation | Menheniott, Trevelyan R., Louise O’Connor, Yok Teng Chionh, Jan Däbritz, Michelle Scurr, Benjamin N. Rollo, Garrett Z. Ng, et al. “Loss of Gastrokine-2 Drives Premalignant Gastric Inflammation and Tumor Progression.” Journal of Clinical Investigation 126, no. 4 (March 14, 2016). © 2016 American Society for Clinical Investigation |
| As Published | http://dx.doi.org/10.1172/jci82655 |
| Publisher | American Society for Clinical Investigation |
| Version | Final published version |
| Accessed | Fri Dec 14 00:01:15 EST 2018 |
| Citable Link | http://hdl.handle.net/1721.1/108195 |
| Terms of Use | Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. |
| Detailed Terms | |
Loss of gastrokine-2 drives premalignant gastric inflammation and tumor progression

Trevelyan R. Menheniott,1,2 Louise O’Connor,1 Yok Teng Chionh,1 Jan Dääbritz,1,2 Michelle Scurr,1 Benjamín N. Rollo,1 Garrett Z. Ng,1 Shelley Jacobs,1 Angelique Catubig,1 Bayzar Kurklu,1 Stephen Mercer,1 Toshinari Minamoto,3 David E. Ong,4 Richard L. Ferrero,5 James G. Fox,4 Timothy C. Wang,7 Philip Sutton,1,8 Louise M. Judd,1,2 and Andrew S. Giraud1,2

1 Murdoch Children’s Research Institute, Melbourne, Victoria, Australia. 2 Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia. 3 Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan. 4 University Medicine Cluster, Division of Gastroenterology and Hepatology, National University Hospital Singapore, Singapore. 5 Centre for Innate Immunity and Infectious Diseases, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia. 6 Division of Comparative Medicine, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 7 Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, New York, USA. 8 Centre for Animal Biotechnology, School of Veterinary and Agricultural Science, University of Melbourne, Parkville, Victoria, Australia.

Chronic mucosal inflammation is associated with a greater risk of gastric cancer (GC) and, therefore, requires tight control by suppressive counter mechanisms. Gastrokine-2 (GKN2) belongs to a family of secreted proteins expressed within normal gastric mucosal cells. GKN2 expression is frequently lost during GC progression, suggesting an inhibitory role; however, a causal link remains unsubstantiated. Here, we developed Gkn2 knockout and transgenic overexpressing mice to investigate the functional impact of GKN2 loss in GC pathogenesis. In mouse models of GC, decreased GKN2 expression correlated with gastric pathology that paralleled human GC progression. At baseline, Gkn2 knockout mice exhibited defective gastric epithelial differentiation but not malignant progression. Conversely, Gkn2 knockout in the IL-11/STAT3-dependent gp130−/− GC model caused tumorigenesis of the proximal stomach. Additionally, gastric immunopathology was accelerated in Helicobacter pylori–infected Gkn2 knockout mice and was associated with augmented T helper cell type 1 (Th1) but not Th17 immunity. Heightened Th1 responses in Gkn2 knockout mice were linked to deregulated mucosal innate immunity and impaired myeloid-derived suppressor cell activation. Finally, transgenic overexpression of human gastrokines (GKNs) attenuated gastric tumor growth in gp130−/− mice. Together, these results reveal an antiinflammatory role for GKN2, provide in vivo evidence that links GKN2 loss to GC pathogenesis, and suggest GKN restoration as a strategy to restrain GC progression.

Introduction

Gastric cancer (GC) has one of the highest rates of neoplasia-related mortality worldwide (1). Chronic inflammation after infection with Helicobacter pylori is an established risk factor for the most common or “intestinal-type” GC (2), initiating progression to atrophic gastritis, intestinal metaplasia, and adenocarcinoma (2). Nevertheless, causal mechanisms linking inflammation to GC progression remain incompletely understood. GC is believed to be of epithelial origin, deriving clonally from gastric epithelial cells (GECs) or their progenitors (3, 4). Therefore, elucidation of factors that counteract the immune-related premalignant transformation of GECs (2) is of high priority for the advancement of GC therapies and improved survival.

Gastrokins (GKNs) are small (~18-kDa) proteins belonging to the BRICHOS protein superfamily, characterized by an approximately 100–amino acid BRICHOS domain, with established links to inflammatory disease, dementia, and cancer (5, 6). While all BRICHOS proteins are secreted or processed to generate secreted mature peptides, GKNs are unique in being almost exclusively expressed within, and secreted by, mucus-producing epithelial cell lineages of the stomach (6–9). The 3 GKNs are encoded by a tightly linked gene cluster on human chromosome 2p13.3 and show broad evolutionary conservation in mammals and higher vertebrates (6, 10). GKN1 and GKN2 were identified in differential expression screens as novel genes downregulated in GC (7, 8, 11). The recently discovered GKN3 was found in a bioinformatic scan for novel BRICHOS proteins. Mouse Gkn3, in contrast to the other GKNs, is overexpressed in atrophic gastritis associated with H. pylori infection (9, 10). While broadly functional in mammals, human GKN3 persists only as a nonexpressed pseudogene (9, 10).

Abundantly expressed in surface mucus cells (SMCs) of the normal human stomach, GKN1 and GKN2 show coordinate downregulation in H. pylori infection, frequent loss of expression in gastric adenocarcinoma, and silencing in tumor cell lines (8). Conversely, an expression microarray study identified GKN2 as the most upregulated gene in the gastric transcriptome after eradication of H. pylori and resolution of mucosal inflammation (12). These observations argue that GKNs and, in particular, GKN2, function either as homeostatic regulators of mucosal immunity and/or as stomach-specific tumor-suppressor genes (TSGs). Bioactivities attributed to GKNs include growth suppression, inhibition of epithelial-to-mesenchymal transition, migration, and invasion of tumor cells (reviewed in ref. 6). While ostensibly supportive of TSG or anticancer roles, these functional observations derive

Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: May 12, 2015; Accepted: February 4, 2016.
mostly from studies in transformed cell lines and, thus, have limited in vivo relevance. Modes of action of GKNs are poorly understood, with cognate receptors and signal transduction pathways remaining elusive (see commentary in ref. 6). However, reports of a gastric secreted GKN2/trefoil factor 1 (TFF1) heterodimer (13, 14) have suggested that GKN2 might act via homeostatic and/or tumor-suppressor activities of TFFs. Current literature implicates GKN2 loss as a determinant of GC pathogenesis, yet evidence of a causal role is lacking. Despite their likely clinical importance, none of the GKNs have been tested functionally in mouse genetic models. As such, physiological and pathological roles of GKN2 (and of other GKNs) remain unsubstantiated in vivo.

To address the impact of GKN2 loss on GC pathogenesis in vivo, here we report the generation and phenotype analysis of Gkn2 knockout mice. Our studies show that GKN2 has antiinflammatory activity in the stomach sufficient to restrain progression of cytokine-driven gastric tumorigenesis and H. pylori infection–related premalignancy. Moreover, transgenic expression of human GKN2s in a validated gastric tumor model restrains pathological progression. The mechanism for GKN2 activity involves expansion and activation of suppressive myeloid cells and inhibition of antigen-presenting cells (APCs), including macrophages and DCs, leading to, leading to attenuated mucosal Th1 immunity. These studies reveal antiinflammatory and tumor inhibitory roles for GKN2 and elucidate GKN2 loss as a key event underlying GC progression.

Results

Conserved GKN2 expression loss in human and mouse GC progression. Human GKN2 and mouse Gkn2 are highly conserved in their genomic organization, intron/exon structure, and genetic linkage to other GKN paralogs (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI82655DS1) and are thus predicted to show similar regulation in vivo. Mouse genetic models have revealed key mechanisms underlying the premalignant transformation of GECs (15–19) and collectively reproduce many of the histopathologic features of human GC progression (Supplemental Figure 2). To confirm clinical relevance and establish a rationale for using a mouse genetic approach to Gkn2 loss, we compared GKN2 expression in human and mouse GC pathogenesis. Quantitative RT-PCR (QRT-PCR) revealed progressive loss of Gkn2 mRNA in human gastric epithelial tissues from individuals with H. pylori infection/gastritis (fold change 3.61 ± 0.56; P < 0.001) and intestinal metaplasia (fold change -10.62 ± 3.51; P < 0.001) relative to normal (disease-free) controls; therefore, expression of this lacZ reporter gene (β-gal) in SMCs (Figure 2, L–N). Overlapping distribution of GKN2 and β-gal expression was noted in the majority of gastric tumors (GC; fold change -84,223 ± 31,909; P < 0.001; Figure 1A). Loss of Gkn2 mRNA was also reflected at the protein level. Immunohistochemical staining revealed abundant GKN2 expression in SMCs of normal antral mucosa, whereas GKN2 expression was reduced in H. pylori–infected tissues and absent in the majority of intestinal metaplasia and GC tissues (Figure 1B).

In mice, GKN2 protein was also stomach specific (Figure 1C), and, as previously shown in humans (15), it localized to SMCs of the gastric corpus and antrum (Figure 1D). We assessed Gkn2 mRNA expression levels in mouse H. pylori infection, transgenic, and knockout models, which collectively reproduce H. pylori inflammatory, premalignant, and tumorigenic stages of human GC. QRT-PCR revealed progressive loss of Gkn2 mRNA from the proximal or corpus stomach, commencing between 7 days and 2 months after infection (MPI) with mouse-adapted H. pylori Sydney strain 1 (SS1), with more pronounced loss (in whole stomach) at 12 MPI (Figure 1E). Similarly, decreased Gkn2 mRNA expression occurred in stomachs of mice with genetic induction of gastric inflammation (stomach-overexpressing H’K’ATPase β subunit [Atp4b] promoter Gm-CSf/transgenic [Gm-CSf/Gkn2] mice), atrophy/metaplasia/hyperplasy (HKβ mice), and tumorigenesis (gp130β mice; HKβ promoter IL1β transgenic [IL1β/Gkn2] mice) (Figure 1F). Gkn2 mRNA expression was unchanged in the distal (antral) stomach during the early stages of H. pylori infection (7 days and 2 MPI; Figure 1E) but strongly downregulated in antral tumors of gp130β mice (Figure 1F). Therefore, Gkn2/Gkn2 expression levels were inversely correlated with (H. pylori–related) gastric pathology. These results reveal conservation of GKN2 loss in GC pathogenesis in humans and mice, thereby validating a mouse genetic approach to investigate GKN2 loss in vivo.

Targeted deletion of the mouse Gkn2 locus. We derived a Gkn2 knockout allele using VelociGene embryonic stem cell lines (Knockout Mouse Project) in which Gkn2-coding exons were replaced with a lacZ reporter and floxed neomycin selection cassette. The neomycin cassette was excised by crossing Gkn2 mice with germ-line-specific Cre-recombinase–deleter transgenic mice (20), and the resulting progeny were mated to obtain homozygous mutants (Figure 2, A and B). Homozygous Gkn2 mice were functionally null, showing a complete absence of GKN2 protein in gastric lyses, but expressed normal levels of GKN1 and GKN3 proteins (Figure 2C). Additionally, Gkn2 mice showed normal fertility, viability, and postnatal survival (Supplemental Tables 1 and 2 and Supplemental Figure 3). To identify cell lineages primarily affected by targeting the Gkn2 locus, we histochemically assessed lacZ reporter gene (β-gal) expression by staining whole-mount stomachs with X-gal (Supplemental Methods). Consistent with the pattern of endogenous Gkn2 expression (Figure 1D), we observed intense β-gal expression in the corpus and antral-pyloric mucosa of Gkn2 mice (Figure 2, D and E), which ceased abruptly at the proximal limiting ridge at the corpus/forestomach (Figure 2F) and pyloric/duodenal (Figure 2G) junctions, respectively. Histological analysis showed specific localization of β-gal expression to SMCs of the corpus (Figure 2, H and I) and antrum (Figure 2, J and K). Double staining in Gkn2 mice confirmed overlapping distribution of GKN2 and β-gal in SMCs (Figure 2, L-N). Therefore, expression of this Gkn2-lacZ reporter/null allele mirrors that of endogenous GKN2 protein, suggesting that gastric SMC is the only lineage autonomously affected by GKN2 loss of function in Gkn2 mice.

Gkn2 mice show impairment of gastric epithelial differentiation that does not progress to malignant disease. Stomachs from 6-, 12-, and 30-week-old Gkn2 mice were examined by standard histopathology. Although cell-autonomous TSG roles have been long suspected of GKN family proteins (6), Gkn2 mice showed no evidence of spontaneous gastric tumors to support this supposition. Gkn2 mice presented with clear abnormalities of the corpus mucosa, including focal hypertrophic lesions, which were evident macroscopically and histologically. Lesions were first apparent at 6 weeks of age and persisted, but did not increase in severity, in mice.
remained significantly elevated in 30-week-old Gkn2−/− mice (Figure 3C). Overall corpus mucosal thickness in Gkn2−/− mice was not significantly different than that of age-matched WT mice (Figure 3D). Nonetheless, corpus mucosal defects, and lesion areas in particular, were associated with an increased epithelial proliferation rate in 6- and 12-week-old but not 30-week-old Gkn2−/− mice (Figure 3E). By contrast, the antral mucosa of Gkn2−/− mice had a
normal histological structure, thickness, and epithelial proliferation count (Figure 3, A, B, D, and E). A detailed study of gastric epithelial markers and cellular changes underlying atrophy and metaplasia was performed in 12-week-old Gkn2−/− mice (in which mucosal lesions and glandular defects are most pronounced). Expression of the gastric trefoil factor (Tff1, Tff2) and mucin genes (Muc1, Muc5ac, Muc6) was not significantly altered, at least in bulk gastric tissue (Figure 4A). However, the SMC metaplasia (showing ectopic Alcian blue staining) was associated with a selective loss of MUC5AC, but not TFF1, specifically within lesion areas by immunofluorescent staining (Figure 4B). Similarly, MNC hyperplasia and glandular atrophy were, respectively, characterized by quantifying expansion of MNC zone and cellular loss within both parietal cell and zymogenic cell compartments (Figure 4C). The modest reduction in parietal cell number was not associated with changes in either stomach acid content (Figure 4D and Supplemental Methods) or antral expression of gastrin (Figure 4E), the principal endocrine stimulator of acid production. Collectively, we believe that these results identify GKN2 as a novel regulator of gastric epithelial homeostasis.

Proximal gastric tumorigenesis in GKN2-deficient gp130−/− mice. Given the role of GKN2 in maintenance of gastric epithelial homeostasis, we asked whether GKN2 genetic loss might potentiate the effects of oncogenic pathways known to induce gastric epi-
Figure 3. Gkn2<sup>−/−</sup> mice display impaired basal gastric epithelial differentiation. (A) Representative images of the gastric mucosa of 6-, 12-, and 30-week-old Gkn2<sup>−/−</sup> and WT littermate control mice. Boundaries between corpus and antral mucosae are delineated with white dashed lines; hypertrophic mucosal lesions are shown by black dashed lines. Scale bar: 5 mm. (B) Low-power images showing AB-PAS–stained Gkn2<sup>−/−</sup> hypertrophic lesions compared with nonlesion and WT corpus mucosa. Scale bar: 200 μm. High-power images of corpus and antrum mucosa in 12-week-old Gkn2<sup>−/−</sup> and WT mice. Scale bar: 50 μm. (C) Summary of semiquantitative histopathology scores for corpus inflammation (inflamm), atrophy, MNC hyperplasia (MNC hyp), and SMC metaplasia (SMC met) in 6-, 12-, and 30-week-old WT and Gkn2<sup>−/−</sup> mice (group sizes as stated in D). (D) Morphometric analysis of corpus and antral mucosal thickness in 6-, 12-, and 30-week-old Gkn2<sup>−/−</sup> (n = 11, n = 9, n = 7) and WT mice (n = 7, n = 9, n = 8). Histograms show mean mucosal thickness as histological cross-sectional area/mm<sup>2</sup> per mm length of muscularis mucosae. Representative images of 12-week-old WT and Gkn2<sup>−/−</sup> corpus and Gkn2<sup>−/−</sup> lesion mucosa are shown. Scale bar: 100 μm. Error bars represent mean ± SEM. P values were determined using a 2-tailed Student’s t test: *P < 0.05; **P < 0.01; ***P < 0.001.
ReseaR ch aR ticle

ReseaR ch aR ticle

thelial tumors in mice. The IL-11/gp130/STAT3 axis is a key driver of GC pathogenesis (15, 16). Mice carrying a knockin mutation at the gp130 cytokine coreceptor locus (gp130<sup>F/F</sup>) show STAT3 hyper-activation and spontaneous tumorigenesis in the antrum, which progresses to encompass the entire secretory mucosa. In the antral stomach, gp130/STAT3 activation is dependent on the cytokine IL-11 (21–23), and the knockin mutant progresses through chronic inflammation, metaplasia, and dysplasia to carcinoma in situ, phenocopying all but the metastatic stage of human intestinal-type GC development (16). In contrast to gp130<sup>F/F</sup> single mutants, which mainly show antral tumors, Gkn2<sup>–/–</sup> gp130<sup>F/F</sup> compound mutants additionally showed extensive focal tumorigenesis of the corpus and squamous epithelium overlying the limiting ridge of the corpus/forestomach junction at 12 weeks of age (Figure 5A). This phenotype was supported quantitatively by an increase in the number of corpus tumor foci (Figure 5B) and an increased macroscopic corpus tumor area in Gkn2<sup>–/–</sup> gp130<sup>F/F</sup> mice (Figure 5C). Histological analysis of the tumors revealed a poorly differentiated and hyperplastic epithelium (Figure 5, D and E), contributing to a significant increase in corpus mucosal thickness overall (Figure 5F). In contrast, the antral tumor load and mucosal thickness in Gkn2<sup>–/–</sup> gp130<sup>F/F</sup> mice were not significantly different than those of gp130<sup>F/F</sup> single mutants (Figure 5, A, C, and F). To further characterize the corpus tumor lineage, we examined the β-gal reporter expression profile of Gkn2<sup>–/–</sup> gp130<sup>F/F</sup> stomach tissues by staining with X-gal. Strikingly, while adjacent normal mucosa retained strong reporter expression, corpus (and antral) tumors were comprised predominantly by unstained cells (Figure 6, A–E). Consistent with the absence of reporter expression (which marks the SMC lineage), the tumors also lacked MUC5AC staining, although TFF1 expression was retained, while both proteins were abundantly expressed in adjacent nontumoral mucosa (Figure 6, F and G).
We found no evidence of mucus metaplasia within the tumor masses, as shown by a lack of TFF2/Griffonia simplicifolia lectin II (TFF2/GSII) staining, although clusters of TFF2/GSII-positive cells were seen at the tumor margins and in adjacent nontumoral mucosa (Figure 6, G and I). Similarly, none of the Gkn2−/− gp130F/F tumors showed evidence of true intestinal metaplasia, as evidenced by absence of CDX2 expression (Figure 6, I and J).

**Absence of synergistic phenotypes in compound mutant Gkn2−/− Tff1−/− mice.** We examined the effect of GKN2 genetic deficiency in the Tff1−/− gastric tumor model. Our rationale was 3-fold: (a) Tff1−/− mice show gastric epithelial hyperplasia progressing to antral tumorigenesis at 3 to 6 months of age (17); (b) TFF1 shows closely overlapping cellular expression with GKN2 (13), raising the possibility of potentiation of individual pathological outcomes; (c) GKN2 and TFF1 have been reported to form heterodimers (14), suggesting cooperative function. Compound mutant Gkn2−/− Tff1−/− mice showed no differences in tumor incidence, mucosal thickness, or temporal progression at 12 weeks of age compared with single mutant Tff1−/− or Gkn2−/− mice (Supplemental Figure 5). Therefore, GKN2 deficiency does not significantly influence tumorigenesis in Tff1−/− mice and vice versa.
arguing that GKN2-TFF1 heterodimers are not, at least in mice, required for individual component suppressive function.

*H. pylori*-infected Gkn2−/− mice show accelerated progression to atrophic gastritis and metaplasia. Having shown that GKN2 restrains the progression of cytokine-driven proximal gastric tumorigenesis, we investigated Gkn2 genetic loss in the context of *H. pylori*-dependent gastritis, a key premalignant lesion of GC (24). Three independent cohorts of 6- to 8-week-old Gkn2−/− and WT control mice were orally infected with *H. pylori* SS1 (25), sacrificed at 2 MPI (Figure 7A), and examined for gastric histopathology. Infected Gkn2−/− mice showed increased severity of atrophic gastritis and pervasive frequent Alician blue–positive mucus metaplasia (consistent with spasmodic polypeptide expressing metaplasia; ref. 26). By contrast, infected WT mice showed relatively mild inflammatory pathology, infrequent atrophy, and metaplasia (Figure 7B), consistent with the known temporal progression of this infection in C57BL/6 mice (25). Accordingly, infected Gkn2−/− mice had higher scores of corpus polymorphonuclear and mononuclear infiltrate, glandular atrophy, and mucus metaplasia, while antral inflammatory scores, though increased from uninfected levels, were similar in Gkn2−/− and WT mice (Figure 7C). Consistent with the severity of atrophy and metaplasia, infected Gkn2−/− mice showed increased expression of mucin 6 (Muc6) mRNA and decreased expression of zymogenic cell and parietal cell lineage markers Mist1 and HKβ1, respectively (Figure 7D). Infected Gkn2−/− mice also had lower *H. pylori* colonization levels (Figure 7E), which were inversely correlated with gastritis severity (Figure 7F), suggesting preferential immune-mediated reduction in bacterial load and/or loss of niche due to mucosal damage. Collectively, these results demonstrate a previously undescribed antinflammatory function of GKN2, which suppresses *H. pylori*-related inflammation and premalignant disease progression in the stomach.

Hyperactivated Th1 immunity in *H. pylori*-infected Gkn2−/− mice. *H. pylori*-related gastritis is typically driven by a dual T helper cell type 1 (Th1) and Th17 immune response, while Th1 and Th17 pathways are modulated by Th2 and Treg cytokine responses. To better understand mechanisms underlying augmented inflammatory responses in Gkn2−/− mice, we first measured levels of anti-*H. pylori* IgG antibody subclasses. Relative to that in WT mice, infected Gkn2−/− mice presented with an antibody response that was skewed toward the IgG2c subclass, which is consistent with an increased Th1 immune response (Figure 8A). To consolidate this finding, we quantified by QRT-PCR expression levels of cytokines and transcription factors that are markers for Th1, Th2, Th17, and Tregs as well as markers of associated M1- and M2-type macrophage responses. Infected Gkn2−/− mice expressed higher mRNA levels of proinflammatory Th1 markers *Ifng* and *Hkf2* (Figure 8B) as well as the M1-associated *Il1b*, *Il6*, *Iil1*, and *Cxcl2* (Figure 8C) and antimicrobial peptide genes *Dmbt1* and *Reg3g* (Figure 8D) compared with infected WT or uninfected controls. *Il10* and *Foxp3* were also preferentially induced, consistent with an attempt by Foxp3+ Tregs to limit inflammatory damage ensuing from the elevated Th1 response (Figure 8E). By contrast, neither Th2 (Figure 8F) nor Th17 lineage markers (Figure 8G) showed broad expression differences in infected Gkn2−/− mice compared with infected WT mice. Therefore, neither Th2 nor Th17 immunity was differentially activated in infected Gkn2−/− mice. However, M2-related arginase 1 (*Arg1*), a key suppressor of T cell responses (27), showed significantly decreased expression in infected Gkn2−/− mice (Figure 8F), again

"Downloaded from http://www.jci.org on January 19, 2017. https://doi.org/10.1172/JCI82655"
consistent with the proinflammatory phenotype of this model. Given that effects of GKN2 deficiency are predominantly on corpus pathology, none of the above immune markers were differentially expressed in the antra of infected Gkn2−/− mice (Supplemental Figure 7). Accelerated progression to atrophic gastritis and mucus metaplasia in Gkn2−/− mice after 2-month H. pylori infection. (A) Strategy used for 2-month H. pylori SS1 infections. (B) Macroscopic and histological images of Gkn2−/− and WT littermate stomachs infected for 2 months and uninfected control stomachs. White dashed lines delineate corpus/antrum boundaries. Arrows show the region of corpus hypertrophy in the infected Gkn2−/− stomach macroscopic photo. Scale bar: 5 mm (macroscopic images); 50 μm (histological images). (C) Semi-quantitative histological assessment of gastric histopathology: inflammatory infiltrate (polymorphonuclear cells [PMN]; mononuclear cells [MN]), atrophy (degree of parietal/zymogenic cell loss), and mucus metaplasia (Met). Histograms show mean pathology scores for each parameter (range 0–4). (D) QRT-PCR analysis of metaplasia (Muc6) and glandular atrophy-related (Mist1 and HKβ) genes in Gkn2−/− mice after 2 months of H. pylori infection. Histograms show mean mRNA fold change relative to WT uninfected mice. (E) H. pylori SS1 colonization levels in stomachs after 2 months of infection, as assessed by Q-PCR (Supplemental Methods). Histograms show mean colonization level (104 H. pylori genomes per 105 Gapdh copies). (F) Linear regression analysis of corpus inflammation score and colonization level. The correlation coefficient (r) value is shown. Error bars represent mean ± SEM. P values were determined using a 2-tailed Student’s t test (C) or 2-tailed Mann Whitney U test (D and E). Statistical significance compared with WT uninfected control mice: *P < 0.05. Statistical significance between treatment groups: **P < 0.01; ***P < 0.001.
Gkn2–/– mice show heightened mucosal innate immunity and impaired myeloid-derived suppressor cell responses. To elucidate mechanisms initiating Th1 inflammatory responses in Gkn2–/– mice, we examined the early phase of immune activation at 7 days after H. pylori infection (28). We hypothesized that GKN2 genetic loss might enhance chemokine release from GECs. To address this, we compared the chemokine/chemokine secretory responses of primary GECs derived from Gkn2–/– and WT mice in a H. pylori SS1 coculture assay (Supplemental Figure 7A). Primary GEC cultures were prepared using established methods (29). Purity of the epithelial cultures was confirmed by staining for pan-cytokeratin and absence of CD45 (immunocytes) and smooth muscle actin (mesenchymal cells). The presence of (GKN2-secreting) SMCs was verified by staining for GKN2 or β-gal in WT and Gkn2–/– cultures, respectively (Supplemental Figure 7B). Unstimulated Gkn2–/– and WT GECs showed no differences in secretion of 23 chemokines/cytokines at baseline, and, while GECs coincubated with live H. pylori for 24 hours showed increased production of CCL3, CCL4, IL-1α, IL-1β, TNF-α, IL-6, and IL-10, these outputs were similar in Gkn2–/– and WT cultures (Supplemental Figure 7C). Therefore, the proinflammatory phenotype of Gkn2–/– mice is unrelated to chemokine secretion by GECs.

is a key mechanism driving myeloid cell recruitment to the gastric mucosa and plays a pivotal role in triggering the host innate response to H. pylori infection (28). We hypothesized that GKN2 genetic loss might enhance chemokine release from GECs. To address this, we compared the chemokine/chemokine secretory responses of primary GECs derived from Gkn2–/– and WT mice in a H. pylori SS1 coculture assay (Supplemental Figure 7A). Primary GEC cultures were prepared using established methods (29). Purity of the epithelial cultures was confirmed by staining for pan-cytokeratin and absence of CD45 (immunocytes) and smooth muscle actin (mesenchymal cells). The presence of (GKN2-secreting) SMCs was verified by staining for GKN2 or β-gal in WT and Gkn2–/– cultures, respectively (Supplemental Figure 7B). Unstimulated Gkn2–/– and WT GECs showed no differences in secretion of 23 chemokines/cytokines at baseline, and, while GECs coincubated with live H. pylori for 24 hours showed increased production of CCL3, CCL4, IL-1α, IL-1β, TNF-α, IL-6, and IL-10, these outputs were similar in Gkn2–/– and WT cultures (Supplemental Figure 7C). Therefore, the proinflammatory phenotype of Gkn2–/– mice is unrelated to chemokine secretion by GECs.

Figure 8. Differential expression of cytokines and immune transcription factors in Gkn2–/– mice after 2-month H. pylori infection. (A) ELISA detection of serum IgG antibody responses in Gkn2–/– mice infected for 2 months. Box plots show median (horizontal bars), interquartile range (boxes) and 10th/90th percentile (error bars) titers of individual anti-H. pylori IgG2c (Th1) and IgG1 (Th2) and combined IgG2c/IgG1 ratio. (B–F) QRT-PCR cytokine/chemokine/transcription factor expression profiles of Gkn2–/– mice infected for 2 months. (B) Th1 markers (Ifng, Tbet); (C) M1 markers (Il1b, Cxcl2, Il6, Il11); (D) antimicrobial lectins (Reg3g, Dmbt1); (E) Treg markers (Il10, Foxp3); (F) Th2/M2 markers (Arg1, Il4, Il5, Fizz1, Ym1, Il1m); and (G) Th17 markers (Rorc, Il17a, Il17f). Histograms show mean mRNA fold change relative to WT uninfected mice. Error bars represent mean ± SEM. P values were determined using a 2-tailed Student’s t test: *P < 0.05; **P < 0.01.
decreased bacterial density occurs prior to the establishment of overt gastritis. To exclude impaired bacterial adhesion to GECs as a mechanism of decreased colonization, we quantified the adhesion of live \textit{H. pylori} to MKN28 GECs transfected with inducible \textit{Gkn2} expression constructs (Supplemental Methods) and found after infection with \textit{H. pylori} (ref. 30 and Figure 9A). \textit{H. pylori} colonization levels were again reduced in \textit{Gkn2}–/– mice infected for 7 days (Figure 9B and Supplemental Figure 8) in the absence of evident inflammation. Therefore, the \textit{Gkn2}–/– gastric niche appears less receptive, even to acute \textit{H. pylori} colonization, suggesting that decreased bacterial density occurs prior to the establishment of overt gastritis. To exclude impaired bacterial adhesion to GECs as a mechanism of decreased colonization, we quantified the adhesion of live \textit{H. pylori} to MK28 GECs transfected with inducible \textit{Gkn2} expression constructs (Supplemental Methods) and found
that *H. pylori* adhesion was not regulated by GKN2 (Supplemental Figure 9). To characterize immune profiles associated with this host response, we assessed cytokine levels in stomachs of uninfected mice and mice infected for 7 days by luminex array analysis (Supplemental Methods). TNF-α, IL-6, IL-1α, CXCL1, and CCL4 were elevated specifically in corpus (but not antrum) tissues of uninfected Gkn2−/− mice, showing no additional increase at 7 days after *H. pylori* infection (Figure 9C and Supplemental Figure 10). Gkn2−/− mice also had basal increases of IL-10, which decreased to WT levels at 7 days after infection (Figure 9D), concomitant with increased production of IFN-γ (Figure 9E). These results are consistent with basal immunoregulation (to counteract elevated proinflammatory cytokines), which rapidly breaks down upon *H. pylori* challenge, allowing enhanced priming of Th1 immunity.

We next investigated whether the altered gastric cytokine profile of Gkn2−/− mice was due to effects in epithelial or immune cells. To address this question, we isolated gastric epithelial and immune cell populations from stomachs of infected mice by FACS (full methods; Figure 10). We observed that the altered cytokine profile of Gkn2−/− mice was specific to immune cells, with increased expression of IL-6, IL-1α, CXCL1, CCL4, and IFN-γ in immune cells but not epithelial cells. These results suggest that the altered cytokine profile of Gkn2−/− mice is due to effects on immune cells, with increased production of cytokines such as IL-6, IL-1α, CXCL1, CCL4, and IFN-γ. These results are consistent with basal immunoregulation (to counteract elevated proinflammatory cytokines), which rapidly breaks down upon *H. pylori* challenge, allowing enhanced priming of Th1 immunity.

To identify specific immune cell subsets, we next assessed gastric mucosal myeloid and lymphoid populations by flow cytometry (full methods; Figure 10). We observed that the altered cytokine profile of Gkn2−/− mice was specific to immune cells, with increased expression of IL-6, IL-1α, CXCL1, CCL4, and IFN-γ in immune cells but not epithelial cells. These results suggest that the altered cytokine profile of Gkn2−/− mice is due to effects on immune cells, with increased production of cytokines such as IL-6, IL-1α, CXCL1, CCL4, and IFN-γ. These results are consistent with basal immunoregulation (to counteract elevated proinflammatory cytokines), which rapidly breaks down upon *H. pylori* challenge, allowing enhanced priming of Th1 immunity.

We next investigated whether the altered gastric cytokine profile of Gkn2−/− mice was due to effects in epithelial or immune cells. To address this question, we isolated gastric epithelial and immune cell populations from stomachs of infected mice by FACS (full methods; Figure 10). We observed that the altered cytokine profile of Gkn2−/− mice was specific to immune cells, with increased expression of IL-6, IL-1α, CXCL1, CCL4, and IFN-γ in immune cells but not epithelial cells. These results suggest that the altered cytokine profile of Gkn2−/− mice is due to effects on immune cells, with increased production of cytokines such as IL-6, IL-1α, CXCL1, CCL4, and IFN-γ. These results are consistent with basal immunoregulation (to counteract elevated proinflammatory cytokines), which rapidly breaks down upon *H. pylori* challenge, allowing enhanced priming of Th1 immunity.

To identify specific immune cell subsets, we next assessed gastric mucosal myeloid and lymphoid populations by flow cytometry (full methods; Figure 10). We observed that the altered cytokine profile of Gkn2−/− mice was specific to immune cells, with increased expression of IL-6, IL-1α, CXCL1, CCL4, and IFN-γ in immune cells but not epithelial cells. These results suggest that the altered cytokine profile of Gkn2−/− mice is due to effects on immune cells, with increased production of cytokines such as IL-6, IL-1α, CXCL1, CCL4, and IFN-γ. These results are consistent with basal immunoregulation (to counteract elevated proinflammatory cytokines), which rapidly breaks down upon *H. pylori* challenge, allowing enhanced priming of Th1 immunity.

To identify specific immune cell subsets, we next assessed gastric mucosal myeloid and lymphoid populations by flow cytometry (full methods; Figure 10). We observed that the altered cytokine profile of Gkn2−/− mice was specific to immune cells, with increased expression of IL-6, IL-1α, CXCL1, CCL4, and IFN-γ in immune cells but not epithelial cells. These results suggest that the altered cytokine profile of Gkn2−/− mice is due to effects on immune cells, with increased production of cytokines such as IL-6, IL-1α, CXCL1, CCL4, and IFN-γ. These results are consistent with basal immunoregulation (to counteract elevated proinflammatory cytokines), which rapidly breaks down upon *H. pylori* challenge, allowing enhanced priming of Th1 immunity.
infected $Gkn2^{-/-}$ mice could be due to APC-mediated skewing away from a tolerogenic Treg response toward a proinflammatory Th1 response. However, in fact, uninfected $Gkn2^{-/-}$ mice had a higher gastric mucosal prevalence of CD4$^+$CD25$^+$Foxp3$^+$ Tregs, which was sustained in mice infected for 7 days (Figure 9G). Therefore, the proinflammatory phenotype of $Gkn2^{-/-}$ mice is independent of gastric Treg responses.

Myeloid-derived suppressor cells (MDSCs) are a mixed population of immature myeloid lineages, including granulocyte, macrophage, and DC progenitors (27). MDSCs dampen proinflammatory strategy shown in Supplemental Figure 12). An increased prevalence of CD11b$^+$F4/80$^+$Gr1$^-$ macrophages and CD11c$^+$ DCs was found in $Gkn2^{-/-}$ mice compared with that in WT mice (Figure 9F and Supplemental Figure 13), suggesting that tissue-resident APCs might play a role in shaping the temporal onset, magnitude, and specific polarity of inflammatory responses in $Gkn2^{-/-}$ mice.

Induction of immune tolerance to $H. pylori$ via recruitment of CD4$^+$CD25$^+$Foxp3$^+$ Tregs occurs during the initial phases of infection, leading to delayed onset of inflammatory pathology (31). We hypothesized that accelerated onset and severity of gastritis in $Gkn2^{-/-}$ mice could be due to APC-mediated skewing away from a tolerogenic Treg response toward a proinflammatory Th1 response. However, in fact, uninfected $Gkn2^{-/-}$ mice had a higher gastric mucosal prevalence of CD4$^+$CD25$^+$Foxp3$^+$ Tregs, which was sustained in mice infected for 7 days (Figure 9G). Therefore, the proinflammatory phenotype of $Gkn2^{-/-}$ mice is independent of gastric Treg responses.

Figure 11. Reduced antral tumor growth in human $GKN2$/$GKN1$-overexpressing BACT$^+$ gp130$^{+/+}$ mice. (A) Representative images of stomachs from line 5 and line 9 BACT$^+$ gp130$^{+/+}$ compound transgenic mice and gp130$^{+/+}$ single mutant littermate controls are shown; black dashed lines delineate tumor margins. Scale bar: 5 mm. (B) Weight of fresh stomach in grams. (C) Macroscopic area of antral tumors in mm$^2$. (D) Weight of fresh spleen in grams in line 5 and line 9 BACT$^+$ gp130$^{+/+}$ compound transgenic ($n = 16/n = 16$) mice, gp130$^{+/+}$ single mutants ($n = 12/n = 12$), BACT$^+$ mice ($n = 7/n = 14$), and WT ($n = 5/n = 12$) littermate controls. (E) Tumor histology in representative BACT$^+$ gp130$^{+/+}$ compound transgenic mice and gp130$^{+/+}$ single mutants. Scale bar: 200 μm. (F) Morphometric analysis of antral mucosal thickness. Histograms show the mean mucosal thickness as the histological cross section area in mm$^2$ per unit length of muscularis mucosae. Biological replicates per group as stated for (D). Error bars represent mean ± SEM. $P$ values were determined using a 1-tailed Mann Whitney U test (B and D) or 1-tailed Student’s t test (C and F): *$P < 0.05$; **$P < 0.01$. 

jci.org  Volume 126  Number 4  April 2016  1395

Downloaded from http://www.jci.org on January 19, 2017.  https://doi.org/10.1172/JCI82655
tory T cell responses (including Th1 immunity against *H. pylori*; ref. 32) via production of arginase, inducible nitric oxide synthase, and immunosuppressive cytokines (27). In mice, monocytic and granulocytic MDSC subsets can be discriminated by CD11b<sup>+</sup>Ly6C<sup>+</sup>Ly6G<sup>−</sup>Cd49d<sup>−</sup> and CD11b<sup>+</sup>Ly6C<sup>−</sup>Ly6G<sup>−</sup>Cd49d<sup>+</sup> surface phenotypes, respectively (33). We assessed MDSCs in stomachs of uninfected *Gkn2<sup>−/−</sup>* mice and *Gkn2<sup>−/−</sup>* mice infected for 7 days by flow cytometry. The total number of MDSCs was significantly reduced in uninfected *Gkn2<sup>−/−</sup>* mice, due to specific deficiency in the monocytic MDSC subset (Figure 9H and Supplemental Figure 13), an effect that was sustained after *H. pylori* infection. These data were corroborated by reduced gastric mRNA expression of the MDSC markers Ccr2 and *Il4ra* (33) in uninfected *Gkn2<sup>−/−</sup>* stomachs compared with WT stomachs (Figure 9J). We surmised that enhanced inflammatory responses in *Gkn2<sup>−/−</sup>* mice could therefore be linked to compromised MDSC responses. Consistent with this expectation, markers of MDSC activation and expansion, *Slc7a9* and *Slc1a9*, were upregulated in WT stomachs infected for 7 days but conversely were downregulated in infected *Gkn2<sup>−/−</sup>* stomachs. Similarly, arginase genes (*Arg1* and *Arg2*) and immunosuppressive cytokines (*Tgfβ1* and *Tgfβ2*) were upregulated (or trended toward increased expression) in WT stomachs infected for 7 days but were either unchanged or downregulated in infected *Gkn2<sup>−/−</sup>* stomachs (Figure 9I). These data suggest that impaired activation of MDSCs and breakdown of IL-10–mediated immunoregulation, combined with reciprocal enrichment of APCs (macrophages and DCs), contribute to an enhanced Th1 response in *H. pylori*-infected *Gkn2<sup>−/−</sup>* mice.

Overexpression of human GKNs restrains gastric tumor growth in vivo. Having established that GKN2 loss can promote GC pathogenesis, we asked whether restoration of GKN2 expression in vivo might suppress disease progression. We reasoned that because GKN2 is normally expressed at unusually high levels, in a discrete and lineage-restricted manner, clinically meaningful outcomes might only be achieved if overexpression to restore GKN2 is driven at a sufficiently high level and in the appropriate cellular context, i.e., specifically in gastric SMCs. We addressed this problem by engineering a large (152-kb) BAC transgene encompassing the entire human GKN2 and GKN1 genomic region (Figure 10A). This strategy, resulting in combined human GKN2 and GKN1 expression, was necessary to include sufficient flanking sequence (i.e., containing all native regulatory elements) to drive an amplitude and lineage specificity of overexpression that cannot be accomplished using conventional transgenic approaches. Two BAC transgenic (*BACTg*) founder lines with a high level of transgene expression, line 5 and line 9, were identified by QRT-PCR and immunoblotting studies (Figure 10, B and C). As surmised above, the BAC transgene directed human GKN2 (and GKN1) mRNA/protein expression exclusively to the stomach, with absolute specificity to gastric SMCs (Figure 10D), thus replicating their endogenous expression. BAC<sup>76</sup> mice displayed normal gastric mucosal histology at 12 weeks of age (Figure 10E), showing that overexpression of human GKNs does not alter basal gastric homeostasis. To investigate the impact of human GKN overexpression on gastric tumorigenesis, we generated two independent BAC<sup>76</sup>*gp130<sup>−/−</sup>* compound mutant strains using BAC<sup>76</sup> mice from line 5 and line 9, respectively. Representative stomachs collected from both BAC<sup>76</sup>*gp130<sup>−/−</sup>* compound mutant strains are shown in Figure 11A.

Antral tumor growth was significantly reduced in 12-week-old BAC<sup>76</sup>*gp130<sup>−/−</sup>* compound mutants, as assessed by reduced total stomach weight (Figure 11B) and macroscopic area of the tumor mass (Figure 11C) compared with *gp130<sup>−/−</sup>* single mutant control mice. Interestingly, the splenomegaly that is typically observed in *gp130<sup>−/−</sup>* mice was significantly reduced in BAC<sup>76</sup>*gp130<sup>−/−</sup>* compound mutants, consistent with an effect of the reduced tumor load on systemic immunity (Figure 11D). Reduced tumor mass in BAC<sup>76</sup>*gp130<sup>−/−</sup>* mice was particularly evident in histological analysis, with both compound transgenic lines showing decreased overall thickness of the antral mucosa compared with *gp130<sup>−/−</sup>* single mutants (Figure 11, E and F). These results establish restoration of human GKNs as a potential therapeutic approach to suppress gastric tumor growth.

Discussion

In a knockout mouse model, we have demonstrated an unexpected antiinflammatory function for the gastric mucus cell-associated protein, GKN2 (8). We have presented in vivo evidence that GKN2 loss, in the context of chronic inflammation induced by *H. pylori* infection, or cytokine-directed tumorigenesis plays a causal role in GC progression. Using a transgenic approach, we have additionally shown that dual overexpression of GKN2 and GKN1 can significantly restrain gastric tumor growth in vivo. This study provides the first major in vivo functional analysis of any of the GKN family proteins to our knowledge. The findings highlight the potential clinical application of these epithelial-derived secreted factors to subdue gastric inflammation and consequent malignant progression.

GKN2 was first linked to GC more than a decade ago, following its initial discovery as a protein downregulated in gastric adenocarcinomas (8, 34). Subsequent studies have shown GKN2 expression loss to be one of the most frequent alterations in both adenocarcinomas (6, 13, 35, 36) and gastric tumor cell lines (6, 35), while, conversely, GKN2 overexpression inhibits proliferation, migration, and invasion of cell lines and tumor xenografts (8, 34, 35). GKN2 therefore appeared to satisfy several of the requisite criteria of a TSG, ostensibly being expressed in normal cell lineages (GECs) giving rise to cancer, imposing restraint on proliferation, and showing absence from tumor cells. Nevertheless, for a genuine TSG function to be formally ascribed, a causal link between expression loss/protein inactivation in a tumor progenitor cell and subsequent oncogenic transformation of derived lineages must be unequivocally established. We instead found that GKN2 loss, in isolation from oncogenic or inflammatory drivers, is insufficient for cell-autonomous transformation, since *Gkn2<sup>−/−</sup>* mice lacked spontaneous tumor growth or significant epithelial hyperplasia, even at advanced (>30 weeks) age.

Previous studies have focused exclusively on a putative and, now debatable, “classical TSG” function for GKN2 (reviewed in ref. 6) but have not considered alternative roles. Our findings here reveal previously undescribed antiinflammatory and mucosal homeostatic activities as the principal in vivo functions of GKN2. Effects of GKN2 deficiency were relatively mild at baseline, characterized mainly by impaired gastric epithelial differentiation. However, loss of GKN2 was found to profoundly exacerbate gastric immunopathology when placed in context of an inflammatory challenge, namely *H. pylori* infection or genetically induced
hyperactivation of oncogenic gp130/STAT3 signaling. Interestingly, Gkn2–/– heterozygous mice (not described in Results section), though phenotypically normal at baseline (Supplemental Figure 14), showed increased susceptibility to H. pylori–dependent immunopathology, which is of intermediate severity to that displayed by WT and Gkn2–/– mice (Supplemental Figure 15). These data argue that even partial loss of GKN2, as typically seen from the onset of premalignant disease, may be clinically significant.

Genetic loss of GKN2 in gp130+/– mice elicited rapid tumorigenesis of the corpus mucosa but, interestingly, did not alter antral tumor growth. However, GKN2 expression is already substantially reduced in gp130+/– antral tumors, such that loss of the residual expression in Gkn2–/– gp130+/– mice would have had little additional impact on tumor growth. As such, these contrasting effects of GKN2 deficiency in corpus and antrum likely relate to the preexisting gp130+/– antral pathology and should not necessarily be taken as evidence of preferential GKN2 activity in the corpus. Indeed, our BAC transgenic studies suggest that GKN2 has similar antitumor activity in antral mucosa. Our dual GKN1/GKN2 transgenic strategy has not allowed explicit attribution of the tumor inhibition to GKN2. However, the clear dosage effects of GKN2 shown here (Supplemental Figure 15) argue that transgenic excess of GKN2 would have likely contributed to the reduced tumor load in some manner. It is noteworthy that GKN1 and GKN2 display identical expression in normal gastric SMCs and show coordinate expression loss in GC (7). As such, our tumor rescue data affirm the translational rationale for combined GKN1/GKN2 overexpression in GC. Additionally, these studies provide functional validation for earlier clinical associations of higher level GKN1/GKN2 expression and better outcome in human GC (37).

Strikingly, corpus and antral tumors induced in Gkn2–/– gp130+/– mice lacked expression of the Gkn2–lacZ reporter allele, yet regions of adjacent nontumoral mucosa retained reporter expression. These observations could suggest inactivation of GKN2 within a tumor progenitor cell but are equally consistent with expansion of tumors from immature epithelial lineages lacking GKN2 expression. Long-lived gastric epithelial progenitor cells and bone marrow–derived cells, neither of which express GKN2, have been implicated in the origin of GC (37, 38). Evidence also exists to support transdifferentiation of mitotically quiescent zymogenic cells (zymogenic cell) into a metaplastic lineage that ultimately gives rise to GC (39). On the other hand, the current literature does not support an origin of GC from short-lived gastric SMCs, the sole GKN2-expressing gastric lineage. We therefore propose that GKN2 may not be “inactivated” in a tumor progenitor but rather that the epithelial progenitors to GC have never expressed GKN2, thereby explaining its absence in gastric tumors. Accordingly, GKN2 may instead act non–cell autonomously as an antiinflammatory paracrine signal that maintains homeostatic epithelial turnover and prevents malignant transformation.

Our finding of accelerated immunopathology in H. pylori–infected Gkn2–/– mice supports an antiinflammatory role for GKN2. Infected Gkn2–/– mice showed enhanced mucosal Th1 responses, as evidenced by markedly elevated Ifng and Tbet mRNA, concomitant skewing toward the IgG2c subclass in the H. pylori antibody humoral response, and reduced H. pylori colonization. IFN-γ is a key determinant of H. pylori–related pathology; H. pylori–infected Ifng–/– mice do not develop gastritis (40), while transgenic overexpression of IFN-γ is sufficient for induction of atrophic gastritis and metaplasia independently of H. pylori infection (41). Thus, elevated IFN-γ is likely central to the premalignant phenotype of infected Gkn2–/– mice, especially given that Th17 cytokines were not differentially induced. The localization of immunopathological responses in the corpus in Gkn2–/– mice is highly reminiscent of that associated with corpus-predominant gastritis in humans, which is similarly characterized by a Th1-skewed response and carries high risk of progression to advanced metaplasia, dysplasia, and intraepithelial tumor growth (42). Our data indicate that, even partial GKN2 expression loss, particularly in the context of Th1-type cytokine gene polymorphisms (43, 44), may strongly influence premalignant outcomes in H. pylori–infected individuals with corpus-predominant disease.

In short-term (7-day) infection studies, we found that Th1 immune bias in Gkn2–/– mice may relate to heightened basal innate immunity. Gkn2–/– mice showed mucosal enrichment of proinflammatory cytokines and increased prevalence of macrophages and DCs, which likely prime an exaggerated IFN-γ response upon exposure to H. pylori. Both macrophages and DCs, via professional antigen-presenting capabilities, are known to initiate adaptive responses against H. pylori, in part by secretion of Th1-polarizing (and Th17-polarizing) cytokines, IL-12 (and IL-23), respectively (45–48). Basally increased IL-10 (and mucosal Tregs) may also explain why Gkn2–/– mice resist pathological progression when unchallenged. Another factor contributing to the Gkn2–/– phenotype may have been MDSCs, which inhibit T cell proliferation in mouse models of GC (19) and suppress effector T cells, which drive gastric immunopathology (49, 50). Impaired gastric MDSC responses to H. pylori infection may have contributed to the accelerated T cell–driven immunopathology in this model. Although MDSCs have been widely described to exacerbate cancer progression via suppression of CD8+ T cell–mediated antitumor immunity and promotion of angiogenesis (27), recent work suggests that MDSCs, via secretion of IL-10, may also participate in the resolution of bacterial inflammation (51). Proinflammatory roles of MDSCs in established H. pylori infections have been proposed by others (32, 52). Our data argue that immunosuppressive functions of MDSCs are required to dampen early gastric responses to H. pylori infection. Given that gastric SMCs are the sole physiological source of GKN2 (see Figure 1D; Figure 2, D–N; refs. 6, 9, and literature cited therein), it is reasonable to argue that altered gastric mucosal immune profiles of Gkn2–/– mice relate to paracrine deficiency of secreted GKN2 protein. Understanding the molecular basis of GKN2 paracrine activity toward specific myeloid cell subsets, including MDSCs, will be a priority if its clinical potential is to be realized.

Functional effects of GKN2 loss have been firmly established here, yet a key question not addressed by this study is what triggers GKN2 loss (or decreased expression) in the first place? Neither cytogenetic aberrations encompassing chromosome 2p13.3 (where the GKNs are located) nor GKN2 somatic mutations have been reported in GC (53–55), while epigenetic silencing of GKN2 applies to only a minority of gastric tumors (55). Together, these studies argue that mechanisms other than cytogenetic or epigenetic anomalies are mainly responsible for GKN2 expression loss. Our findings of decreased Gkn2 mRNA in IIIb and Gm-CSF
transgenic overexpressing mice or following IL-11/gp130/STAT3 hyperactivation (see Figure 1F) suggest a mechanism of negative transcriptional regulation via proinflammatory cytokine signaling. This is corroborated by earlier work showing transcriptional repression of a GKN2 promoter-reporter construct induced by exogenous IL-1β, IL-6, and TNF-α treatment or NF-κB cotransfection in cultured GECs (56). The appropriate expression dosage of GKN2 protein (and associated anti-inflammatory activity) may therefore be governed by promoter cis elements, functioning collectively as a cytokine-responsive "transcriptional rheostat." Such a mechanism could explain the progressive loss of GKN2, in concert with worsening inflammation, as well as the recovery of GKN2 expression after H. pylori eradication and restoration of mucosal homeostasis (12).

In summary, we demonstrate an anti-inflammatory role for the gastric epithelial-secreted protein, GKN2. We provide the first in vivo functional evidence to our knowledge that loss of GKN2 expression, leading to deregulated Th1 immunity and exacerbation of inflammatory pathology, plays a causal role in GC progression. Critically, we have also shown that restoration of human GKN expression can interrupt gastric tumor growth in vivo. Current preventative therapy for GC is based on antibiotic eradication of H. pylori (57). Our findings suggest complementation of GKN2 function as an alternative disease management strategy, particularly in the approximately 20% of infected individuals for whom antibiotic treatment fails (57) or in those presenting with irreversible premalignant disease (58).

Methods

Human tissues. H. pylori–infected and disease-free human gastric epithelial tissues, GCSs, and premalignant “adjacent-to-cancer” tissues with intestinal metaplasia were obtained endoscopically (59, 60).

Gene targeting. Embryonic stem cell clones (C57BL/6NTac genetic background) carrying a VelociGene lacZ reporter/loxP-flanked neomycin selection cassette (61) at the Gkn2 locus were purchased from the Knockout Mouse Project repository (https://www.komp.org/). Injection of targeted embryonic stem cell clones into BALB/c recipient blastocysts and backcrossing (C57BL/6) of resulting chimeric mice to generate Gkn2−/− mice was performed at the Australian Phenomics Network laboratories, Monash, Clayton, Victoria, Australia (http://www.australianphenomics.org.au/).

Generation of BAC transgenic mice. A 152-kb DNA fragment containing the human GKN1 and GKN2 genomic region was excised from the vector backbone by pulsed field gel electrophoresis through a 1% agarose, Tris/borate/EDTA gel. Purified BAC DNA was subjected to tube dialysis against 100 volumes microinjection buffer (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.1 mM EDTA, 30 μM spermine) overnight at 4°C. Dialyzed BAC DNA was diluted to a concentration 0.5 ng/μl and then used for microinjection into C57BL/6J × DBA/2J F2 hybrid zygotes. BAC lines founder animals were identified by PCR and Southern blotting analysis. Two founder lines (lines 5 and 9) with high-level expression of human GKNs were selected and backcrossed to the C57BL/6J strain for 6 generations prior to commencement of experiments. To generate BAC lines 5 and 9 BACs compound transgenic mice, BAC line 5 and BAC line 9 mice (C57BL/6) were each independently crossed with gp130−/− mice (C57BL/6).

Mice. Mouse strains, including the gp130−/− mutant (a gift from Mathias Ernst, Olivia Newton John Cancer Research Institute, Melbourne, Australia; ref. 15), HKβ−/− (a gift from Ian van Driel, Bio21 Molecular Science and Biotechnology Institute, Melbourne, Australia; ref. 62), TgCMV-cre1Cgn transgenic (CMV-CreRα; a gift from Ursula Lichtenberg, University of Cologne, Cologne, Germany; ref. 20), Tff1−/− (17), Gkn2−/− (generated in-house), and human GKN2/GKN1 BAC transgenic mice (generated in-house), were maintained on a C57BL/6 genetic background. All strains were housed under specific pathogen–free conditions. Gastric tissues from HKβ promoter Gm-CSf transgenic (Gm-CSfF/F) mice (BALB/c strain background) (63) were a gift from Ian van Driel. Gastric tissues were also obtained from HKβ promoter IL1β transgenic (IL1F/F) mice that have been described previously (19). All experiments involving the above strains used matched WT littermate controls.

H. pylori infection in mice. Mouse-adapted H. pylori SS1 (vacA+, cagPAI dysfunctional; ref. 25) was grown in brain-heart infusion broth (Oxoid) containing 5% horse serum (JRH Biosciences) and 0.02% amphostat (Invitrogen), under microaerophilic conditions for 24 hours at 37°C. Mice were infected intra-gastrically with a single dose of 108 H. pylori SS1 CFU suspended in 100 μl brain-heart infusion broth as described previously (64). H. pylori colonization levels were subsequently quantified by TaqMan quantitative PCR assay on stomach extracts (full details provided in the Supplemental Methods) or by CFU assay as described previously (64).

Histopathology. Stomach tissues were collected at necropsy, fixed in 4% paraformaldehyde in PBS overnight, and processed for standard paraffin wax histology. Slides were stained for presence of neutral (gastric-type) and acidic (intestinal-type) mucins with Alcian blue PAS (AB-PAS) reagent and scored for pathology on a scale of 0 to 4 by a blinded observer as described previously (65), with modifications (full details, including criteria for individual scores, are provided in the Supplemental Methods).

Immunohistochemistry and immunofluorescence. Immunohistochemistry was performed as described previously (9). Bound immunocomplexes were detected using Vectastain ABC reagents (Vector Laboratories), and staining was visualized by incubation in 3',3'-diaminobenzidine tetrahydrochloride reagent (Sigma-Aldrich). Immunofluorescence in cultured cells was performed as described previously (9). Primary antibodies and lectins used are as follows: rabbit polyclonal anti-mouse GKN2 (R771-B3) and anti-human GKN2 (R779-B3; custom generated, see Supplemental Methods), each diluted 1:500; mouse monoclonal anti-human Ki67 (Abcam) diluted 1:500; lectin GS–II from Griffonia simplicifolia (EY Labs) used at 10 μg/ml; sheep polyclonal anti-human pepsinogen II (Abcam) diluted 1:100; mouse monoclonal anti-HKα ATPase β subunit (Abcam, ab2866) diluted 1:2,000; rabbit polyclonal anti-TFF1 and TFF2 (custom generated) (60) diluted 1:750 and 1:1,000, respectively; mouse monoclonal anti-MUC5AC-biotin conjugate (Abcam, ab79082) diluted 1:400; rabbit monoclonal anti-CDX2-Alexa Fluor 488 conjugate (Abcam, ab195007) diluted 1:200; and chicken polyclonal anti-β-gal (Abcam, ab9361) diluted 1:200. Immunofluorescence detection of bound primary antibodies was achieved using the following secondary antibody conjugates: donkey anti-rabbit IgG-Alexa Fluor 594, goat-anti mouse IgG Alexa Fluor 488, streptavidin-Alexa Fluor 488, streptavidin-Alexa Fluor 568, and anti-sheep IgG Alexa Fluor 594 (all from Invitrogen.
Molecular Probes) and goat anti-chicken IgY-DyLight 488 (Abcam, ab96947). Samples were mounted in Pro-Long Gold medium containing DAPI counterstain (Invitrogen). Fluorescence images were captured using a Zeiss LSM 780 laser scanning confocal microscope and processed using ZEN software (Zeiss).

**Flow cytometry.** Cell suspensions were prepared from whole stomach tissue using Gentle MACS lamina propria dissociation reagents and protocols (Miltenyi Biotec). Total leukocytes were purified from cell suspensions by Percoll (GE Healthcare) density gradient centrifugation (40%/80% Percoll interface) and then resuspended in 2% FBS, 2 mM EDTA in HBSS. Purified leukocytes were stained for presence of surface markers specific to macrophages, DCs, and MDSCs using the following anti-mouse monoclonal antibodies: CD11b (Brilliant Violet 421 101235 [1:1,000]; PE 557397 [1:500]), CD49d (FITC, 103605 [1:1,000]), Gr1 (PerCP-Cy5.5, 552093 [1:1,000]), Ly6C (PerCP, 128028 [1:1,000]), F4/80 (Aluca Fluor 700, 123130 [1:1,000]), Ly6G (APC/Cy7, 127624 [1:500]), and CD45 (V500, 561487 [1:500]) (all Biolegend) and CD11c (APC, 17-0114-82 [1:1,000]) (eBioscience). Tregs were detected using the Mouse Regulatory T Cell Staining Kit (eBioscience, 88-8111-40: CD4 [FITC (1:500)], CD25 [APC (1:100)], and Foxp3 (PE [1:200]). CountBright absolute counting beads (Molecular Probes) were used to determine total cell number per sample. Cell viability was assayed by propidium iodide dye exclusion. Leukocytes were gated based on forward and side scatter properties, with subsequent gating on specific myeloid cell markers as described above (gating strategies are shown in Supplemental Figure 12). Data collection was performed on a BD LSR II Flow Cytometer, and analysis was performed using FACSDiva software (both BD Biosciences).

**Gene expression.** QRT-PCR was performed as described previously (66). Primer sequences were designed using the primer3 tool (http://frodo.wi.mit.edu/primer3/) and are listed together with cycling parameters in the Supplemental Methods. Relative gene expression was normalized to expression of internal reference gene GAPDH (human) or RpL32 (mouse) using the −2ΔΔCt method, where −2ΔΔCt = ΔCt sample − ΔCt calibrator (67).

**Statistics.** Data were analyzed with GraphPad Prism V5.1 software. Data are presented as the mean ± SEM. Statistical analysis was performed by 1-way analysis of variance, with 2-group comparisons tested post hoc, using a 1- or 2-tailed Student’s t-test for parametric data or a Mann-Whitney U test for nonparametric data. P values of 0.05 or lower were considered statistically significant.

**Study approval.** Mouse experiments were approved by the Murdoch Children’s Research Institute Ethics Committee (approval no. A693, A700, and A713). Approval for experiments on human tissues was obtained from the Royal Melbourne Hospital Human Research Ethics Committee (approval no. 2004.176) and the Kanazawa University Ethics Committee for Human Genome Research (approval no. 174.2008). Written informed consent was obtained for all study participants.

**Author contributions** TRM and LOC performed most of the experiments and data analysis. YTC, MS, LMJ, JD, BNR, GZN, SJ, AC, DEO, BK, and SM contributed to experiments. LMJ, JD, and MS contributed to data analysis. JGF, TCW, TM, and RLF contributed reagents, materials, or protocols. TRM, PS, LMJ, and ASG conceived of, designed, and led the study. TRM wrote the manuscript. TRM, PS, LMJ, ASG, JD, TM, and RLF edited/revised the manuscript.

**Acknowledgments** We thank the Australian Phenomics Network for assistance with generation of Gkn2−/− mice and Elizabeth Williams for pronuclear injections of BAC DNA and generation of transgenic mice at the Transgenic Animal Service of Queensland, University of Queensland, St. Lucia, Australia. We thank Matthew Burton, the Flow Cytometry and Imaging Facility, Murdoch Children’s Research Institute, for advice and assistance with flow cytometry analysis. This study was supported by a project grant (1047208) from the National Health and Medical Research Council (NHMRC); research fellowships awarded to T.R. Menheniott (1026674), A.S. Giraud (607330), L.M. Judd (1008776) and P. Sutton (1020387) by the NHMRC; a fellowship (DFG DA1161/5-1) awarded to J. Dabritz by the German Research Foundation; and the Victorian Government’s Medical Research Operational Infrastructure Support Program.

Address correspondence to: Trevelyan R. Menheniott, Murdoch Children’s Research Institute, The Royal Children’s Hospital, 50 Flemington Road, Parkville, Victoria, 3052, Australia. Phone: 61.3.9936.6265; E-mail: treve.menheniott@mcrl.edu.au.
33. The Journal of Clinical Investigation